You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab

Article info

Article menu
Immunotherapy biomarkers
Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab

Authors

  • Eric D Routh Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Mark G Woodcock Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADivision of Medical Oncology, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Wolfgang Beckabir Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Steven P Vensko Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Jonathan S Serody Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADepartment of Microbiology and Immunology, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADivision of Hematology, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  • Benjamin G Vincent Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADepartment of Microbiology and Immunology, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USADivision of Hematology, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USAComputational Medicine Program, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Benjamin G Vincent; benjamin_vincent{at}med.unc.edu
View Full Text

Citation

Routh ED, Woodcock MG, Beckabir W, et al
Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
Journal for ImmunoTherapy of Cancer 2023;11:e005848. doi: 10.1136/jitc-2022-005848

Publication history

  • Accepted January 27, 2023
  • First published March 7, 2023.
Online issue publication 
October 18, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.